Evidence map›Paper›PMID 42310679›Full record

ReviewJournal of translational medicine2026

SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies.

Sushan Wang, Xiaoqing Zhao, Jianhua Dong, Jing Zhang, Yuxin Wang, Honglian Jin, Xinyu Jiang, Li Chen, Ming Zhang, Lei Ji and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sushan Wang *Department of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Xiaoqing Zhao *Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Jianhua DongDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Jing ZhangDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Yuxin WangDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Honglian JinDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Xinyu JiangDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Li ChenDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Ming ZhangDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China.
Lei JiDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. jilei@jlu.edu.cn.
Yawei ZhaoDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun, 130021, China. zhaoyawei@jlu.edu.cn.ORCID 0000-0002-1689-5406

Funding

National Natural Science Foundation of China No. 82204444Reveal the Challenge and Take the Lead Bethune Project of Medicine + X Cross-disciplinary Innovation Team at Jilin Univerity 2024JBGS10Science and Technology Department of Jilin Provincial YDZJ202301ZYTS553
6 · The paper itself

Abstract

backgroundSrc homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) is a critical signaling molecule involved in tumor proliferation, invasion, metastasis, and immune evasion. In gastrointestinal (GI) cancers, however, its function is highly complex and context-dependent, varying across distinct cellular compartments within the tumor microenvironment (TME). MAIN BODY: This review focuses on five major GI malignancies and reframes SHP2 function within a GI-specific TME, emphasizing how its roles are shaped by key environmental determinants-including cell type, tissue microenvironment, and disease state. We further discuss how current therapeutic modalities, such as chemotherapy, radiotherapy, and targeted therapy, modulate SHP2 activity and contribute to treatment resistance. In addition, we evaluate the therapeutic potential of SHP2 inhibition, highlighting recent advances in allosteric inhibitors, emerging combination strategies, and ongoing clinical studies.

conclusionsTogether, this review provides a conceptual framework for understanding SHP2 as both a signaling integrator and a precision therapeutic target in GI cancers, offering insights that may inform future mechanistic studies and the development of context-aware therapeutic strategies.

Indexed as

Gastrointestinal NeoplasmsMolecular Targeted TherapyProtein Tyrosine Phosphatase, Non-Receptor Type 11Tumor MicroenvironmentAnimalsHumansSignal TransductionProtein Tyrosine Phosphatase, Non-Receptor Type 11Gastrointestinal cancerImmunotherapySHP2Tumor microenvironment

Identifiers

PMID42310679
PMCPMC13289118

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.